Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,655 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (720)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07500441 | Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML | recruiting | — | 100 | Peking University People's HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 |
| clinicaltrials |
| NCT03286530 | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | active not recruiting | Phase 2 | 64 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05260528 | CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics(ALFA2101) | recruiting | Phase 2 | 248 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05674175 | Co-administration of CART22-65s and huCART19 for B-ALL | recruiting | Phase 1 / Phase 2 | 93 | Stephan Grupp MD PhDOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03533816 | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | recruiting | Phase 1 | 38 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06313437 | Revumenib in Combination With 7+3 + Midostaurin in AML | recruiting | Phase 1 | 22 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06847269 | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia | recruiting | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07107126 | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | recruiting | Phase 1 | 24 | Remedy Plan, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML(VAG-3+7-G) | not yet recruiting | Phase 3 | 300 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 25, 2026 | clinicaltrials |
| NCT06985485 | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy | recruiting | Phase 2 | 26 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04990102 | Phase IB/II of CPX-351 for Relapse Prevention in AML | recruiting | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07463651 | MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib(TROPHY-15) | recruiting | Phase 3 | 594 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | not yet recruiting | Phase 3 | 204 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07486726 | Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05029141 | New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 21 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05376111 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | recruiting | Phase 2 | 28 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06220162 | VAC Regimen for AML Patients Who Failed to Response to VA Regimen | recruiting | Phase 2 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06440135 | Ziftomenib Maintenance Post Allo-HCT | recruiting | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07483749 | HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors | not yet recruiting | — | 400 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05636514 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS(CELESTIAL-MDS) | recruiting | Phase 1 | 12 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06207123 | A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) | recruiting | Phase 1 / Phase 2 | 15 | University of ChicagoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07270770 | BY002 IIT Study in R/R Acute Leukemia | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479927 | Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy(PsyCARTkids) | recruiting | N/A | 40 | Hospital Universitario La PazOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation(ACCELERATE) | recruiting | Phase 2 | 358 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06918431 | Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | recruiting | Phase 2 | 53 | City of Hope Medical CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT06325280 | Exercise MRI to Evaluate Cardiorespiratory Fitness in Children With Heart Disease | recruiting | — | 20 | University of AlbertaOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06994676 | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias(CROSSCHECK-001) | recruiting | Phase 1 | 72 | Crossbow Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07474051 | Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials(PERSIST) | enrolling by invitation | — | 178 | AvenCell Therapeutics, Inc.INDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT04644016 | Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05451979 | HIIT in Pediatric Heart Transplant Recipients (MedBIKE™) | recruiting | N/A | 10 | University of AlbertaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05735184 | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | recruiting | Phase 1 | 420 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06055621 | Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE(VEN-R DASA) | recruiting | Phase 2 | 35 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06557421 | De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients(STOP VEN) | recruiting | Phase 2 | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07470073 | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults | recruiting | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07471789 | Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). | recruiting | Phase 1 / Phase 2 | 33 | Gyala TherapeuticsINDUSTRY | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03970096 | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | recruiting | Phase 2 | 120 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05292664 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | recruiting | Phase 1 | 30 | Andrew E. Place, MDOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05627232 | Tazemetostat and Palbociclib With CPX-351for R/R AML | recruiting | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06867289 | Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring(DINAMO) | recruiting | N/A | 50 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05535855 | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | recruiting | Phase 1 | 29 | University of Colorado, DenverOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05679895 | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL(CARxALL) | recruiting | Phase 1 | 20 | OneChain ImmunotherapeuticsINDUSTRY | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07372885 | GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia(GRACE) | not yet recruiting | Phase 1 / Phase 2 | 50 | University of ManchesterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07463768 | Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.(MIVONU) | not yet recruiting | Phase 2 | 60 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05748197 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials